VSTM News and Press, Verastem Inc. From 12/29/25

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer...

2025-12-15 16:34:48 ET More on Verastem Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript Verastem, Inc. 2025 Q3 - Results - Earnings Call Presentation Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade) Verastem Oncology...

John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC completes additional patient...

2025-11-26 15:13:03 ET More on Markets The 'Real' Economy Is In Real Trouble Boomer Blues, Not Gen Z? SPYI Vs. SPY: The Case For Covered Calls In Two Charts Mixed signals as S&P 500’s December strength weakens in recent decade Sociét&#...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the 8 th Annual Evercore Healthcare Conference on Tu...

2025-11-19 10:15:25 ET Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – The precision oncology market is accelerating toward $158.9 billion by 2029 as targeted therapies demonstrate unprecedented efficacy in cancers previousl...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its previously announced underwritten public offering of 8,543,794 shares of its common stock at an offering price t...

2025-11-13 16:13:35 ET More on Verastem Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade) Verastem Oncology drops despite Q3 double beat Verastem signals confidence in AVMAPKI FAKZYNJA CO-PACK growth and prepares for pivotal 2026 cl...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, V...

2025-11-04 12:12:01 ET More on Verastem Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript Verastem, Inc. 2025 Q3 - Results - Earnings Call Presentation Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade) Verastem signals ...